• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为调和平均数的平均风险。

Average Hazard as Harmonic Mean.

作者信息

Chiba Yasutaka

机构信息

Clinical Research Center, Kindai University Hospital, Osaka, Japan.

出版信息

Pharm Stat. 2025 Mar-Apr;24(2):e70009. doi: 10.1002/pst.70009.

DOI:10.1002/pst.70009
PMID:40064601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11893520/
Abstract

A new measure was recently developed in the context of survival analysis that can be interpreted as a weighted arithmetic mean of the hazards with the survival function as the weight. However, when the average hazard is desired, it is more appropriate to use the harmonic mean rather than the arithmetic mean. Therefore, in this article, we derive the average hazard as a harmonic mean version of the expectation for hazards and show it to be equal to the previous weighted arithmetic mean. Furthermore, we demonstrate that the average hazard should be estimated using only the times at which the event is observed, while previous studies have allowed estimating the average hazard even when the truncation time is set to a time at which the event is not observed.

摘要

最近在生存分析的背景下开发了一种新的度量方法,它可以解释为以生存函数为权重的风险的加权算术平均值。然而,当需要平均风险时,使用调和平均值比算术平均值更合适。因此,在本文中,我们将平均风险推导为风险期望的调和平均版本,并证明它等于先前的加权算术平均值。此外,我们证明平均风险应该仅使用观察到事件发生的时间来估计,而先前的研究允许即使将截断时间设置为未观察到事件的时间时也估计平均风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb38/11893520/2b222f2deac4/PST-24-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb38/11893520/42a6f9b94556/PST-24-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb38/11893520/2b222f2deac4/PST-24-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb38/11893520/42a6f9b94556/PST-24-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb38/11893520/2b222f2deac4/PST-24-0-g001.jpg

相似文献

1
Average Hazard as Harmonic Mean.作为调和平均数的平均风险。
Pharm Stat. 2025 Mar-Apr;24(2):e70009. doi: 10.1002/pst.70009.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
4
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
5
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
7
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
8
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.3岁以下HIV感染儿童抗逆转录病毒疗法的优化
Cochrane Database Syst Rev. 2014 May 22;2014(5):CD004772. doi: 10.1002/14651858.CD004772.pub4.
9
Sexual Harassment and Prevention Training性骚扰与预防培训
10
Anterior Approach Total Ankle Arthroplasty with Patient-Specific Cut Guides.使用患者特异性截骨导向器的前路全踝关节置换术。
JBJS Essent Surg Tech. 2025 Aug 15;15(3). doi: 10.2106/JBJS.ST.23.00027. eCollection 2025 Jul-Sep.

本文引用的文献

1
Treatment Effect Measures Under Nonproportional Hazards.非比例风险下的治疗效果测量
Pharm Stat. 2025 Mar-Apr;24(2):e2449. doi: 10.1002/pst.2449. Epub 2024 Oct 27.
2
Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy.平均风险与生存权重的比值和差值:量化新疗法生存获益的新指标。
Stat Med. 2023 Mar 30;42(7):936-952. doi: 10.1002/sim.9651. Epub 2023 Jan 5.
3
Treatment effect measures under nonproportional hazards.非比例风险下的治疗效果测量
Pharm Stat. 2023 Jan;22(1):181-193. doi: 10.1002/pst.2267. Epub 2022 Oct 6.